Finlands Akademi
Finansieringsbeslut
 
Namn Metsä-Ketelä, Mikko
Organisation TY
Projektets titel Metabolic Engineering for High-Value Chemical Entities
Beslutnr 304028
Beslutsdatum 30.09.2016
Finansieringsperiod 01.10.2016 - 30.09.2018
Finansiering 299 647
WebFOCUS Report
Beskrivning av projektet
Micro-organisms are able to produce a wide array of compounds that have become highly important for humans. Metabolites derived from Streptomyces bacteria have been approved as antibiotics, anticancer agents, immunosuppressants, antifungal compounds, in the treatment of diabetes and as anthelmintic drugs. In spite of their great success, new chemical entities are urgently needed to counter the rise of antibiotic resistance and to limit the side-effects in cancer chemotherapy. Typically these compounds are produced industrially through a fermentation process, which is cheaper and more environmentally friendly than chemical synthesis. The purpose of this application was to translate 15 years of basic research on antibiotic biosynthesis into applied technology development. During the project we have attempted to use metabolic engineering to improve both the production profile and production levels of two anticancer agents and one antibiotic.